What I think also bodes well for CHM is that our 2101 T-cell construct is already being proven up via our Chlorotoxin-binding product in the clinic treating GBM. Essentially, the differentiator between Arbele's Cabotamig (ARB202) and our CHM2101 is the number and type of intracellular targets.
According to our most recent preso, there are only three competitor therapies currently in development in clinical trials using CDH17 which is significant in itself... but the fact that our CAR construct is interchangeable with CLTX would make it highly attractive to Big Pharma, surely? And, that is exactly what JC highlights in recent interviews and presentations.
What you raise about Merck and Keytruda's upcoming patent expiry is a really great point. I dare say that your statement: "I dare say Merck are keeping a very close eye on how CHM 2101 progresses." is spot on! The reason I say that is: "ARBELE is a biotech company founded in 2016 by former senior executives from Johnson & Johnson, Roche, Sanofi, and Bristol-Myers Squibb." according to this blog:-
Thanks, pinch!
- Forums
- ASX - By Stock
- CHM
- Chimeric: Media Thread
Chimeric: Media Thread, page-688
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CHM (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.8¢ |
Change
-0.002(10.0%) |
Mkt cap ! $15.41M |
Open | High | Low | Value | Volume |
1.9¢ | 1.9¢ | 1.8¢ | $103.4K | 5.657M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 1370830 | 1.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.9¢ | 464912 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 1370830 | 0.018 |
7 | 915219 | 0.017 |
4 | 362631 | 0.016 |
7 | 610170 | 0.015 |
3 | 2499999 | 0.014 |
Price($) | Vol. | No. |
---|---|---|
0.019 | 464912 | 3 |
0.020 | 178304 | 1 |
0.021 | 339793 | 2 |
0.022 | 200000 | 1 |
0.023 | 724246 | 3 |
Last trade - 16.10pm 30/05/2024 (20 minute delay) ? |
|
|||||
Last
1.9¢ |
  |
Change
-0.002 ( 0.00 %) |
|||
Open | High | Low | Volume | ||
1.8¢ | 2.0¢ | 1.8¢ | 4405765 | ||
Last updated 15.53pm 30/05/2024 ? |
Featured News
CHM (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
Previous Video
Next Video
SPONSORED BY The Market Online